Skip to content
Menu

Novartis AG NVS

Full chart Compare
Set alert

Price alert · NVS

All alert types
150.47 USD -0.75 (-0.50%)

Regular-session close

150.00 -0.47 -0.31%

After hours · Nov 20, 7:17 PM ET

150.24 Day range 152.70
124.36 52-week range 168.62
YTD
+9.14%
1 year
+21.00%

Fundamental scorecard

14 of 25 checks passed on NVS’s reported financials

ValueGrowthProfitabilityHealthDividend

14of 25 checks passed

  • Value 1 of 5
  • Growth 3 of 5
  • Profitability 4 of 5
  • Financial health 2 of 5
  • Dividend 4 of 5

Statements to Sep 30, 2026.

Value 1 of 5

  • Failed:P/E below its own 5-year median P/E 28.3 against a 5-year median of 16.3.
  • Failed:P/E under 20 P/E 28.3: an earnings yield of 3.5%.
  • Failed:Price to sales below its own 5-year median Price to sales 5.0 against a 5-year median of 4.5.
  • Failed:Price to book below its own 5-year median Price to book 7.6 against a 5-year median of 4.4.
  • Passed:Free cash flow yield above 4% Free cash flow of 15.7B is 5.5% of the market value.

Growth 3 of 5

  • Passed:Revenue grew over the last year Revenue of 57.4B is +1.8% on the 12 months before.
  • Failed:Revenue grew more than 5% a year over five years +2.6% a year from FY 2020 to FY 2025.
  • Failed:Earnings per share grew over the last year EPS 5.24 against 7.31 in the 12 months before.
  • Passed:Earnings per share grew more than 5% a year over five years +15.2% a year from FY 2020 to FY 2025.
  • Passed:Analysts expect higher earnings per share over the next year The average forward estimate is +89.6% on the last 12 months.

Profitability 4 of 5

  • Passed:Profitable over the last year Net income of 10.0B over the last 12 months.
  • Passed:Profitable in each of the last five fiscal years A profit in 5 of the last 5 fiscal years.
  • Passed:Return on equity above 15% Return on equity of 24.6%.
  • Failed:Net margin above its 5-year average Net margin of 17.5% against a 5-year average of 30.0%.
  • Passed:Free cash flow is at least 80% of net income Free cash flow of 15.7B is 156.4% of net income.

Financial health 2 of 5

  • Failed:Short-term assets cover short-term liabilities Short-term assets of 28.7B against short-term liabilities of 32.5B.
  • Failed:Short-term assets cover long-term liabilities Short-term assets of 28.7B against long-term liabilities of 47.1B.
  • Failed:Net debt under 40% of equity Net debt of 39.3B is 105.7% of equity.
  • Passed:Operating cash flow covers at least 20% of debt Operating cash flow of 17.3B is 35.9% of debt.
  • Passed:Operating profit covers interest at least 3 times Operating profit is 9.0 times the interest expense.

Dividend 4 of 5

  • Passed:Pays a dividend 9.07B paid over the last 12 months.
  • Passed:Yield above 1.5% A yield of 3.2% at the current market value.
  • Failed:Pays out under 75% of profit 90.4% of net income is paid out.
  • Passed:Covered by free cash flow 57.8% of free cash flow is paid out.
  • Passed:Not cut in the last five fiscal years The total paid did not fall in any of the last five fiscal years.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Included in Essentials and up

Sign in to see P/E against peers

The price to earnings ratio beside the closest competitors and their median.

Financial position

What NVS owns and owes, as of Sep 30, 2026

Short term and long term

Balance sheet · 117B of assets

Debt, equity and cash by year

Now: 39.3B of debt after cash

Fiscal years, then the newest quarter. Cash includes short-term investments.

From the company’s SEC filings.

Included in Essentials and up

Sign in to see Cash flow and returns

How profit turns into free cash flow, and the returns on equity, assets and capital.

Financial health

Altman Z-Score

3.47 Safe zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

7 / 9 Strong

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

B+3 / 5 overall

  • DCF 4
  • Return on Equity 5
  • Return on Assets 5
  • Debt / Equity 1
  • P/E 2
  • P/B 1

Valuation

P/E 19.0×
P/S 4.9×
P/B 5.8×
P/FCF 15.1×
EV/EBITDA 12.7×
EV/Sales 5.3×
FCF Yield 6.6%

Profitability

Gross Margin 75.0%
Operating Margin 31.2%
Net Margin 25.6%
ROE 30.5%
ROIC 15.5%
ROA 12.2%

Growth (YoY)

Revenue 6.0%
Operating Income 17.4%
EPS (diluted) 22.5%
Free Cash Flow 28.1%

Financial Health

Current Ratio 1.1×
Quick Ratio 0.9×
Debt / Equity 0.8×
Net Debt / EBITDA 1.1×
Interest Coverage 14.4×

Dividends

Dividend Yield 2.9%
Payout Ratio 55.9%

Annual · latest fiscal year ends 2025-12-31